EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Severe fever with thrombocytopenia syndrome virus: immune evasion, therapeutic landscape, and vaccine prospects

Amin Ullah, Mei Yang, Lili Li, Jian Shang

Frontiers in Cellular and Infection Microbiology · 18.11.2026 · 16

DOI: 10.3389/fcimb.2026.2002250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 18.11.2026. Verfasst von Amin Ullah und 3 weiteren Autor:innen. Die Arbeit nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne bunyavirus that poses a growing public health threat. National surveillance data from China (2010-2023) report an overall case fatality rate of approximately 4.8%. However, hospital-based cohorts of severe or critically ill patients report substantially higher rates, ranging from 12% to 30%. Despite its designation as a WHO priority pathogen in 2017, no vaccine has been approved, although a first-in-human Phase I/II trial of an mRNA vaccine candidate was initiated in 2025, and favipiravir, the only authorized antiviral (Japan, 2024), remains of debated clinical benefit, leaving a widening gap between mechanistic understanding and clinical translation. This gap is rooted in the virus’s ability to dismantle the very immune pathways on which vaccines and antivirals depend. The non-structural protein NSs sequesters TBK1, IRF3, and STAT1/STAT2 into viroplasm-like structures, while the nucleoprotein NP induces autophagy-mediated degradation of cGAS and MAVS, collectively diminishing type I interferon responses, impairing B-cell and T-cell immunity, and permitting the dysregulated cytokine storm that is associated with multi-organ failure. These same mechanisms explain why vaccine candidates that perform well in immunocompromised (IFNAR⁻/⁻ or STAT2⁻/⁻) mouse models have not translated to immunocompetent or aged populations, and why antiviral efficacy collapses at high viral loads or late treatment initiation. Unlike prior reviews that treat pathogenesis, antivirals, and vaccines as separate topics, this review integrates them into a single framework linking viral immune evasion to the failure modes of current countermeasures, and identifies the specific obstacles that must be overcome before clinical translation: missing correlates of protection, immunocompromised animal models, and reassortment-driven antigenic diversity. We conclude by outlining priority directions, including AI-assisted antigen design, host-directed and combination therapies, standardized animal models, and integrated One Health surveillance.

Zitieren

APA

Ullah, A., Yang, M., Li, L., & Shang, J. (2026). Severe fever with thrombocytopenia syndrome virus: immune evasion, therapeutic landscape, and vaccine prospects. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.2002250

Vancouver

Ullah A, Yang M, Li L, Shang J. Severe fever with thrombocytopenia syndrome virus: immune evasion, therapeutic landscape, and vaccine prospects. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.2002250

BibTeX
@article{Ullah2026,
  author = {Ullah, Amin and Yang, Mei and Li, Lili and Shang, Jian},
  title = {Severe fever with thrombocytopenia syndrome virus: immune evasion, therapeutic landscape, and vaccine prospects},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.2002250}
}
Kostenlos starten →